Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Buqué, Aitziber ^a   Aresti, Unai ^a   Calvo, Begoña ^a   Sh Muhialdin, Jangi ^a   Muñoz, Alberto ^a   Carrera, Sergio ^a   Azkona, Eider ^a   Rubio, Itziar ^a   López Vivanco, Guillermo ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; PEMETREXED; PURINE DERIVATIVE; THYMIDYLATE SYNTHASE;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FOLIC ACID ANTAGONISTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; ORGAN SPECIFICITY; PURINES; PYRIMIDINES; THYMIDYLATE SYNTHASE;

EID: 84877653415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063338     Document Type: Article

References (24)

1. Gonen N, Assaraf YG, (2012) Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance. Drug Resist Updat 15: 183-210.
2. Cancer multidrug resistance. Nat Biotechnol 18Suppl: IT18-20.
3. Sen T, Sen N, Brait M, Begum S, Chatterjee A, et al. (2011) DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res 71: 1167-1176.
4. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, et al. (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129: 1500-1515.
5. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, et al. (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 105: 10853-10858.
6. Eberle J, Hossini AM, (2008) Expression and function of bcl-2 proteins in melanoma. Curr Genomics 9: 409-419.
7. Inoki K, Zhu T, Guan KL, (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
8. Nannizzi S, Veal GJ, Giovannetti E, Mey V, Ricciardi S, et al. (2010) Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemother Pharmacol 66: 547-558.
9. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, et al. (2005) Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081-32089.
10. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, et al. (2007) Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 156: 1204-1213.
11. Racanelli AC, Rothbart SB, Heyer CL, Moran RG, (2009) Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69: 5467-5474.
12. Adjei AA, (2004) Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5Suppl 2: S51-55.
13. Buqué A, Muhialdin JS, Muñoz A, Calvo B, Carrera S, et al. (2012) Molecular mechanism implicated in Pemetrexedinduced apoptosis in human melanoma cells. Mol Cancer 11: 25.
14. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, et al. (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68: 110-118.
15. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, et al. (2008) Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 99: 750-759.
16. Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, et al. (2007) In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 25: 417-423.
17. Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, et al. (2010) Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101: 161-166.
18. Van Triest B, Pinedo HM, Giaccone G, Peters GJ, (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11: 385-391.
19. Rattan R, Giri S, Singh AK, Singh I, (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593.
20. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, et al. (2008) Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128: 2013-2023.
21. Plas DR, Thompson CB, (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435-7442.
22. Yang X, Fraser M, Moll UM, Basak A, Tsang BK, (2006) Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136.
23. Rothbart SB, Racanelli AC, Moran RG, (2010) Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res 70: 10299-10309.
24. Beckers A, Organe S, Timmermans L, Vanderhoydonc F, Deboel L, et al. (2006) Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol Cancer Ther 5: 2211-2217.